Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin
2012/12/01 by Katherine A. MacLean, Jeannie‐Marie S. Leoutsakos, Jeannie‐Marie Leoutsakos +2 · 45 citations
Psychology · Medicine · Social Sciences · #Psychedelics and Drug Studies #Cannabis and Cannabinoid Research #Religion, Spirituality, and Psychology
paper · doi:10.1111/j.1468-5906.2012.01685.x
Abstract
A large body of historical evidence describes the use of hallucinogenic compounds, such as psilocybin mushrooms, for religious purposes. But few scientific studies have attempted to measure or characterize hallucinogen-occasioned spiritual experiences. The present study examined the factor structure of the Mystical Experience Questionnaire (MEQ), a self-report measure that has been used to assess the effects of hallucinogens in laboratory studies. Participants (N=1602) completed the 43-item MEQ in reference to a mystical or profound experience they had had after ingesting psilocybin. Exploratory factor analysis of the MEQ retained 30 items and revealed a 4-factor structure covering the dimensions of classic mystical experience: unity, noetic quality, sacredness (F1); positive mood (F2); transcendence of time/space (F3); and ineffability (F4). MEQ factor scores showed good internal reliability and correlated with the Hood Mysticism Scale, indicating convergent validity. Participants who endorsed having had a mystical experience on psilocybin, compared to those who did not, had significantly higher factor scores, indicating construct validity. The 4-factor structure was confirmed in a second sample (N=440) and demonstrated superior fit compared to alternative models. The results provide initial evidence of the validity, reliability, and factor structure of a 30-item scale for measuring single, hallucinogen-occasioned mystical experiences, which may be a useful tool in the scientific study of mysticism.
Cited by
- Immigrant Acculturation and Transnationalism: Israelis in the United States and Europe Compared
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
- Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
- When AI Takes the Couch: Psychometric Jailbreaks Reveal Internal Conflict in Frontier Models
- Cellular mechanisms of serotonergic psychedelics - apical hypercontextualisation
- Dissolving yourself in connection to others: shared experiences of ego attenuation and connectedness during group VR experiences can be comparable to psychedelics
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
- Reframing psychedelic regulation: Tools, not treatments
- Change in occupational burnout measures in emergency medical service workers after a psychedelic experience induced by a single self-administered dose of psilocybin mushrooms
- Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial
- Learning from Boundlessness: Psychedelic induced awe and epistemic shifts towards a holistic worldview
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
- Observational cohort study of a group-based VR program to improve mental health and wellbeing in people with life-threatening illnesses
- <i>Edging thermodynamic equilibrium</i> : mystical experiences as “mirror” encounters between the entropic brain and the entropic world
- Phenomenology, Structure, and Dynamic of Psychedelic States
- Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder
- This is your brain on death: a comparative analysis of a near-death experience and subsequent 5-Methoxy-DMT experience
- Psychedelics and environmental virtues
- Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
- The hidden therapist: evidence for a central role of music in psychedelic therapy
- Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. [europepmc]
- Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. [europepmc]
- Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). [europepmc]
- Long-term follow-up of psilocybin-facilitated smoking cessation. [europepmc]
- Clinical applications of hallucinogens: A review. [europepmc]
- Alterations of consciousness and mystical-type experiences after acute LSD in humans. [europepmc]
- An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. [europepmc]
- Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. [europepmc]
- Long-lasting subjective effects of LSD in normal subjects. [europepmc]
- Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. [europepmc]
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. [europepmc]
- The hidden therapist: evidence for a central role of music in psychedelic therapy. [europepmc]
- The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. [europepmc]
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. [europepmc]
- Subanaesthetic ketamine and altered states of consciousness in humans. [europepmc]
- Predicting Responses to Psychedelics: A Prospective Study. [europepmc]
- 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. [europepmc]
- Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. [europepmc]
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. [europepmc]
- Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. [europepmc]
- Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. [europepmc]
- Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. [europepmc]
- Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. [europepmc]
- Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. [europepmc]
- The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. [europepmc]
Related